Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes

Lancet

Volumn 364, Issue 9428, 2004, Pages 51-62

  Ledergerber, Bruno ^a   Lundgren, J ^o   Sarah Walker, A ^c   Sabin, C A ^o   Justice, Amy ^e   Reiss, Peter ^f   Mussini, Cristina ^g   Wit, Ferdinand ^f   d'Arminio Monforte, Antonella ^h   Weber, Rainer ^a   Fusco, Gregory ⁱ   Staszewski, Schlomo ^j   Law, Matthew ^k   Hogg, Robert ^l   Lampe, Fiona ^d   John Gill, M ^m,ah   Castelli, Francesco ⁿ   Phillips, Andrew N ^d,o   Rooney, P ^o   Taylor, S ^o   Couldwell, D ^o   Austin, D ^o   Block, M ^o   Clemons, J ^o   Finlayson, R ^o   Petoumenos, K ^o   Quan, D ^o   Smith, D ^o   O'Connor, C ^o   Gorton, C ^o   Allen, D ^o   Mulhall, B ^o   Mutimer, K ^o   Jansen, C L ^o   Cooper, D ^o,ae   Carr, A ^o   Miller, J ^o   Pell, C ^o   Ellis, D ^o   Baker, D ^o   Kidd, J ^o   McFarlane, R ^o   Liang, M T ^o   Brown, K ^o   Huffam, S ^o   Savage, J ^o   Morgan, S ^o   Knibbs, P ^o   Sowden, D ^o   Walker, A ^o   Orth, D ^o   Lister, G ^o   Chuah, J ^o   Fankhauser, W ^o   Dickson, B ^o   Bradford, D ^o   Wilson, C ^o   Ree, H ^o   Magon, H ^o   Anderson, J ^o   Moore, R ^o   Russell, D ^o   McGovern, G ^o   McNair, R ^o   Bal, J ^o   Fairley, K ^o   Roth, N ^o   Eu, B ^o   Strecker, S ^o   Wood, H ^o   Mijch, A ^o   Hoy, J ^o   Pierce, A ^o   McCormack, C ^o   Watson, K ^o   Medland, N ^o   Daye, J ^o   Mallal, S ^o   French, M ^o   Skett, J ^o   Maxwel, D ^o   Cain, A ^o   Montroni, M ^o   Scalise, G ^o   Costantini, A ^o   Giacometti, A ^o   Tirelli, U ^o   Nasti, G ^o   Pastore, G ^o   Ladisa, N ^o   Perulli, M L ^o   Suter, F ^o   Arici, C ^o   Maggiolo, F ^o   Chiodo, F ^o   Gritti, F M ^o   Colangeli, V ^o   Fiorini, C ^o   Guerra, L ^o   Carosi, G ^o   Cadeo, G P ^o   Minardi, C ^o   Vangi, D ^o   Paraninfo, G ^o   Casari, S ^o   Pan, A ^o   Patroni, A ^o   Torti, C ^o   Quiros Roldan, E ^o   Tomasoni, L ^o   Moretti, F ^o   Nasta, P ^o   Uccelli, M C ^o   Bertelli, D ^o   Rizzardini, G ^o   Migliorino, G ^o   Migliorino, M ^o   Abeli, C ^o   Manconi, P E ^o   Piano, P ^o   Ferraro, T ^o   Scerbo, A ^o   Pizzigallo, E ^o   Ricci, F ^o   Santoro, D ^o   Pusterla, L ^o   Carnevale, G ^o   Galloni, D ^o   Vigano P ^o   Mena, M ^o   Ghinelli, F ^o   Sighinolfi, L ^o   Leoncini, F ^o   Mazzotta, F ^o,ak   Pozzi, M ^o   Lo Caputo, S ^o   Angarano, G ^o   Grisorio, B ^o   Ferrara, S ^o   Grima, P ^o   Tundo, P ^o   Pagano, G ^o   Piersantelli, N ^o   Alessandrini, A ^o   Piscopo, R ^o   Toti, M ^o   Chigiotti, S ^o   Soscia, F ^o   Tacconi, L ^o   Orani, A ^o   Perini, P ^o   Nigro, M ^o   Scasso, A ^o   Vincenti, A ^o   Scalzini, A ^o   Fibbia, G ^o   Moroni, M ^o   Lazzarin, A ^o   Cargnel, A ^o   Vigevani, G M ^o   Caggese, L ^o   Tordato, F ^o   Novati, R ^o   Galli, A ^o   Merli, S ^o   Pastecchia, C ^o   Moioli, C ^o   Esposito, R ^o   Abrescia, N ^o   Chirianni, A ^o   Izzo, C ^o   Piazza, M ^o   De Marco, M ^o   Montesarchio, V ^o   Manzillo, E ^o   Nappa, S ^o   Colomba, A ^o   Abbadessa, V ^o   Prestileo, T ^o   Mancuso, S ^o   Ferrari, C ^o   Pzzaferri, P ^o   Filice, G ^o   Minoli, L ^o   Bruno, R ^o   Maserati, R ^o   Novati, S ^o   Tinelli, C ^o   Pauluzzi, S ^o   Baldelli, F ^o   Petrelli, E ^o   Cioppi, A ^o   Alberici, F ^o   Ruggieri, A ^o   Menichetti, F ^o   Martinelli, C ^o   De Stefano, C ^o   La Gala, A ^o   Zauli, T ^o   Ballardini, G ^o   Magnani, G ^o   Ursitti, M A ^o   Arlotti, M ^o   Ortolani, P ^o   Ortona, L ^o   Dianzani, F ^o   Ippolito, G ^o   Antinori, A ^o   Antonucci, G ^o   D'Elia, S ^o   Narciso, P ^o   Petrosillo, N ^o   Vullo, V ^o   De Luca, A ^o   Del Forno, L ^o   Zaccarelli, M ^o   De Longis, P ^o   Ciardi, M ^o   D'Offizi, G ^o   Noto, P ^o   Lichtner, M ^o   Capobianchi, M R ^o   Girardi, E ^o   Pezzotti, P ^o,t   Rezza, G ^o,t   Mura, M S ^o   Mannazzu, M ^o   Caramello, P ^o   Sinicco, A ^o   Soranzo, M L ^o   Gennero, L ^o   Sciandra, M ^o   Salassa, B ^o   Grossi, P A ^o   Basilico, C ^o   Poggio, A ^o   Bottari, G ^o   Raise, E ^o   Pasquinucci, S ^o   De Lalla, F ^o   Tositti, G ^o   Resta, F ^o   Chimienti, A ^o   Lepri Cozzi, A ^o   Bachmann, S ^o   Battegay, M ^o   Bernasconi, E ^o   Bucher, H ^o   Burgisser P ^o   Cattacin, S ^o   Egger, M ^o,ad   Erb, P ^o   Fierz, W ^o   Fischer, M ^o   Flepp, M ^o   Fontana, A ^o   Francioli, P ^o,ad   Furrer, H J ^o   Gorgievski, M ^o   Gunthard H ^o   Hirschel, B ^o   Kaiser, L ^o   Kind, C ^o   Klimkait, T ^o   Lauper, U ^o   Opravil, M ^o   Paccaud, F ^o   Pantaleo, G ^o   Perrin, L ^o   Piffaretti, J C ^o   Rickenbach, M ^o,ad   Rudin, C ^o   Schupbach J ^o   Speck, R ^o   Tarr, P ^o   Telenti, A ^o   Trkola, A ^o   Vernazza, P ^o   Yerly, S ^o   de Wolf, F ^o   van Sighem, A I ^o   van Valkengoed, I ^o   Gras, L ^o   Bronsveld, W ^o   Veldkamp, A ^o   Prins, J M ^o   Bos, J C ^o   Schattenkerk Eeftinck, J K M ^o   Godfried, M H ^o   Lange, J M A ^o   Lowe, S H ^o   van der Meer, J T M ^o   Nellen, F J B ^o   Pogany, K ^o   van der Poll, T ^o   Ruys, T A ^o   Sankatsing, S ^o   van der Valk, M ^o   van Vonderen, M G A ^o   Wit, F W M N ^o   van Eeden, A ^o   ten Veen, J H ^o   van Dam, P S ^o   Hillebrand Haverkort, M E ^o   Brinkman, K ^o   Frissen, P H J ^o   Weigel, H M ^o   Mulder, J W ^o   van Gorp, E C M ^o   Meenhorst, P L ^o   Mairuhu, A T A ^o   Veenstra, J ^o   Danner, S A ^o   Van Agtmael, M A ^o   Claessen, F A P ^o   Geerlings, S E ^o   Perenboom, R M ^o   Jurriaans, S ^o   Back, N K T ^o   Cuijpers, T ^o   Rietra, P J G M ^o   Roozendaal, K J ^o   Pauw, W ^o   van Zanten, A P ^o   Smits, P H M ^o   von Blomberg, B M E ^o   Savelkoul, P ^o   Zaaijer, H ^o   Beijnen, J H ^o   Crommentuyn, K M L ^o   Huitema, A D R ^o   Kappelhoff, B ^o   de Maat, M M R ^o   Richter, C ^o   van der Berg, J ^o   van Leusen, R ^o   Swanink, C ^o   Vriesendorp, R ^p   Jeurissen, F J F ^p   Kauffmann, R H ^o   Koger, E L W ^o   Franck, P F H ^o   Lampe, A S ^o   Bravenboer, B ^o   ten Napel, C H H ^o   Mudrikova, T ^o   Hendriks, R ^o   Sprenger, H G ^o   Miesen, W M A J ^o   Schirm, J ^o   Benne, D ^o   ten Kate, R W ^o   Veenendaal, D ^o   van Houte, D P F ^o   Leemhuis, M P ^o   Pole, M ^o   Storm, H ^o   van Zeijl, J H ^o   Kroon, F P ^o   Schippers, E F ^o   Kroes, A C M ^o   Claas, H C J ^o   Schreij, G ^o   van de Geest, S ^o   Verbon, A ^o   Bruggeman, C A M V A ^o   Goossens, V J ^o   Koopmans, P P ^o   Telgt, M ^o   van der Ven, A J A M ^o   Burger, D M ^o   Hugen, P W H ^o   Galama, J M D ^o   Poort, Y A G M ^o   van der Ende, M E ^o   Gyssens, I C ^o   de Marie, S ^o   Nouwen, J L ^o   Niesters, M G ^o   Osterhaus, A D M E ^o   Schutten, M ^o   Juttmann, J R ^o   Buiting, A G M ^o   Swaans, C A M ^o   Schneider, M M E ^o   Bonten, M J M ^o   Borleffs, J C C ^o   Hoepelman, I M ^o   Jaspers, C A J J ^o   Schouten, I ^o   Schurink, C A M ^o   Boucher, C A B ^o   Schuurman, R ^o   Blok, W L ^o   Groeneveld, P H P ^o   Boel, E ^o   Jansz, A F ^o   Dabis, F ^q   Thiebaut, R ^q   Chene G ^q   Lawson Ayayi, S ^q   Meyer, L ^o,r   Boufassa, F ^r   Hamouda, O ^s   Touloumi, G ^u   Hatzakis, A ^u   Karafoulidou, A ^u   Katsarou, O ^u   Brettle, R ^o,v   Del Amo, J ^o,w   del Romero, J ^w   van Asten, L ^x   van Benthem, B ^x   Prins, M ^x   Coutinho, R ^o,x   Kirk, O ^o,y   Pedersen, C ^o,y   Hernandez Aguado I ^z   Perez Hoyos S ^z   Eskild, A ^aa   Bruun, J N ^aa   Sannes, M ^aa   Lee, C ^o,ab   Johnson, A M ^o,ac   Babiker, A ^c,ac   Darbyshire, J ^c,o,ac   Gill, N ^o,ac   Porter, K ^o,ac   Vanhems, P ^o,ad,ag   Kaldor, J ^o,ae   Ashton, L ^o,ae   Vizzard, J ^ae   Muga, R ^af   Cayla, J ^ai   Garcia de Olalla, P ^ai   Day, N E ^aj   De Angelis, D ^aj   Walker, S ^c   Tyrer, F ^c   Beral, V ^o   Raffanti, S ^o   Becker, S ^o   Scarsella, A ^o   Braun, J ^o   Most, B ^o   Balu, R ^o   Gilbert, L ^o   Fleenor, R ^o   Ising, T ^o   Dieterich, D ^o   Fusco, J ^o   Losso, M ^o   Duran, A ^o   Vetter, N ^o   Clumeck, N ^o   De Wit, S ^o   Kabeya, K ^o   Poll, B ^o   Colebunders, R ^o   Machala, L ^o   Rozsypal, H ^o   Nielsen, J ^o   Olsen, C H ^o   Gerstoft, J ^o   Katzenstein, T ^o   Hansen, A B E ^o   Skinhoj P ^o   Zilmer, K ^o   Rauka, M ^o   Katlama, C ^o   De Sa, M ^o   Viard, J P ^o   Saint Marc, T ^o   Pradier, C ^o   Dietrich, M ^o   Manegold, C ^o   van Lunzen, J ^o   Stellbrink, H J ^o   Miller, V ^o   Goebel, F D ^o   Salzberger, B ^o   Rockstroh, J ^o   Kosmidis, J ^o   Gargalianos, P ^o   Sambatakou, H ^o   Perdios, J ^o   Panos, G ^o   Filandras, A ^o   Banhegyi, D ^o   Mulcahy, F ^o   Yust, I ^o   Burke, M ^o   Pollack, S ^o   Hassoun, J ^o   Sthoeger, Z ^o   Maayan, S ^o   Vella, S ^o   Chiesi, A ^o   Pristera R ^o   Gabbuti, A ^o   Bedini, A ^o   Montesarchio, E ^o   Santopadre, P ^o   Franci, P ^o   Castagna, A ^o   Viksna, L ^o   Rozentale, B ^o   Chaplinskas, S ^o   Hemmer, R ^o   Staub, T ^o   Bruun, J ^o   Maeland, A ^o   Ormaasen, V ^o   Knysz, B ^o   Gasiorowski, J ^o   Horban, A ^o   Prokopowicz, D ^o   Wiercinska Drapalo, A ^o   Boron Kaczmarska, A ^o   Pynka, M ^o   Beniowski, M ^o   Trocha, H ^o   Smiatacz, T ^o   Antunes, F ^o   Mansinho, K ^o   Maltez, F ^o   Duiculescu, D ^o   Streinu Cercel, A ^o   Mokras M ^o   Stanekova D ^o   Gonzalez Lahoz J ^o   Diaz, B ^o   Garcia Benayas T ^o   Martin Carbonero, L ^o   Soriano, V ^o   Clotet, B ^o   Jou, A ^o   Conejero, J ^o   Tural, C ^o   Gatell, J M ^o   Miro J M ^o   Zamora, L ^o   Blaxhult, A ^o   Karlsson, A ^o   Pehrson, P ^o   Schiffer, V ^o   Furrer, H ^o   Chentsova, N ^o   Barton, S ^o   Mercey, D ^o   Youle, M ^o   Johnson, M A ^o   Mocroft, A ^o   Murphy, M ^o   Weber, J ^o   Scullard, G ^o   Fisher, M ^o   Loveday, C ^o   Ruiz, L ^o   Helm, E B ^o   Carlebach, A ^o   Mosch M ^o   Muller A ^o   Haberl, A ^o   Korn, S ^o   Stephan, C ^o   Bickel, M ^o   Gute, P ^o   Locher, L ^o   Lutz, T ^o   Klauke, S ^o   Doerr, H W ^o   Sturmer M ^o   Dauer, B ^o   Jennings, B ^o   Alexander, C ^o   Braitstein, P ^o   Chan, K ^o   Cote, H ^o   Gataric, N ^o   Harrigan, P R ^o   Harris, M ^o   Bonner, S ^o   Montaner, J ^o   O'Shaughnessy, M ^o   Wood, E ^o   Yip, B ^o   Chaloner, C ^o   Gumley, H ^o   Ransom, D ^o   Lipman, M ^o   Johnson, M ^o   Read, R ^ah   Riccio, G ^al   Borghi, V ^o   more..

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b HVIDOVRE HOSPITAL   (Denmark)

^c MRC CLINICAL TRIALS UNIT   (United Kingdom)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITY OF AMSTERDAM   (Netherlands)

^g UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

ⁱ GLAXOSMITHKLINE   (United States)

^j GOETHE UNIVERSITY   (Germany)

^k UNIVERSITY OF NEW SOUTH WALES   (Australia)

^l BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^m Southern Alberta Clinic   (Canada)

ⁿ UNIVERSITY OF BRESCIA   (Italy)

^o Southern Alberta Clinic ^*

^p MEDICAL CENTER HAAGLANDEN   (Netherlands)

^q Aquitaine cohort   (France)

^r SEROCO cohort   (France)

^s German cohort   (Germany)

^t Italian Seroconversion Study   (Italy)

^u Greek Haemophilia Cohort   (Greece)

^v Edinburgh Hospital Cohort   (United Kingdom)

^w Madrid Cohort   (Spain)

^x Amsterdam Cohort Studies Among Homosexual Men and Drug Users   (Netherlands)

^y Center for Marginalized Adults and Families   (Denmark)

^z Valencia IDU Cohort   (Spain)

^aa ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^ab Royal Free haemophilia cohort   (United Kingdom)

^ac UK Register of HIV Seroconverters   (United Kingdom)

^ad Swiss HIV cohort   (Switzerland)

^ae Sydney Primary HIV Infection Cohort   (Australia)

^af Badalona IDU Hospital Cohort   (Spain)

^ag Lyon Primary Infection Cohort   (France)

^ah South Alberta Clinic   (France)

^ai Barcelona IDU Cohort   (Spain)

^aj MRC BIOSTATISTICS UNIT   (United Kingdom)

^ak Firenze Tecnologia   (Italy)

^al Unit of Diagnostic and Interventional Radiology   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; ENFUVIRTIDE; HYDROXYUREA; RITONAVIR; TENOFOVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; AUSTRALIA; CELL COUNT; CONTROLLED STUDY; DEMOGRAPHY; EUROPE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONBIOLOGICAL MODEL; NORTH AMERICA; PRIORITY JOURNAL; REGRESSION ANALYSIS; T LYMPHOCYTE; VIRUS LOAD; VIRUS REPLICATION; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COHORT ANALYSIS; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TREATMENT FAILURE; VIROLOGY;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; TREATMENT FAILURE; VIRAL LOAD;

EID: 3042740596     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)16589-6     Document Type: Article

References (47)

1. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA. 288:2002;222-235
2. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet. 353:1999;863-868
3. Staszewski S, Miller V, Sabin C, et al. Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS. 13:1999;367-373
4. Mocroft A, Phillips AN, Friis-Moller N, et al. Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study. Antivir Ther. 7:2002;21-30
5. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med. 317:1987;185-191
6. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet. 343:1994;871-881
7. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet. 348:1996;283-291
8. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 344:2001;472-480
9. Anon. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41: 1-19.
10. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 69:1982;239-241
11. Mocroft A, Gill MJ, Davidson W, Phillips AN. Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care? J Acquir Immune Defic Syndr. 24:2000;475-482
12. Huber PJ. The behaviour of maximum likelihood estimates under non-standard conditions. Proceedings of the fifth Berkeley symposium on mathematical statistics and probability. 1967;221-233 University of California Press, Berkeley, CA
13. White H. Maximum likelihood estimation of misspecified models. Econometrica. 50:1982;1-25
14. Kirk O, Mocroft A, Katzenstein TL, et al. Changes in use of antiretroviral therapy in regions of Europe over time. AIDS. 12:1998;2031-2039
15. Becker SL, Raffanti SR, Hansen NI, et al. Zidovudine and stavudine sequencing in HIV treatment planning: findings from the CHORUS HIV cohort. J Acquir Immune Defic Syndr. 26:2001;72-81
16. Sudre P, Rickenbach M, Taffe P, Janin P, Volkart AC, Francioli P. Clinical epidemiology and research on HIV infection in Switzerland: the Swiss HIV Cohort Study 1988-2000. Schweiz Med Wochenschr. 130:2000;1493-1500
17. Nieuwkerk PT, Sprangers MA, Burger DM, et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med. 161:2001;1962-1968
18. Carosi G, Castelli F, Suter F, et al. Antiviral potency of HAART regimens and clinical success are not strictly coupled in real life conditions: evidence from the MASTER-1 study. HIV Clin Trials. 2:2001;399-407
19. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 286:2001;2568-2577
20. CASCADE Collaboration. Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE. HIV Med 2000; 1: 224-31.
21. The Australian HIV Observational Database. Rates of combination antiretroviral treatment change in Australia, 1997-2000. HIV Med 2002; 3: 28-36.
22. d'Arminio Monforte A, Cozzi-Lepri A, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS. 14:2000;499-507
23. Mocroft A, Youle M, Moore A, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS. 15:2001;185-194
24. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 362:2003;22-29
25. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 360:2002;119-129
26. Lane HC, Masur H, Gelmann EP, et al. Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndrome. Am J Med. 78:1985;417-422
27. Mellors JW, Kingsley LA, Rinaldo CR Jr, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 122:1995;573-579
28. Lundgren JD, Mocroft A, Gatell JM, et al. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. J Infect Dis. 185:2002;178-187
29. Cozzi-Lepri A, Katzenstein TL, Ullum H, et al. The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection. AIDS. 12:1998;1639-1643
30. Yerly S, Perneger TV, Hirschel B, et al. A critical assessment of the prognostic value of HIV-1 RNA levels and CD4+ cell counts in HIV-infected patients. Arch Intern Med. 158:1998;247-252
31. Lawrence J, Mayers DL, Hullsiek KH, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med. 349:2003;837-846
32. Miller V, Phillips AN, Clotet B, et al. Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. J Infect Dis. 186:2002;189-197
33. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 348:2003;2175-2185
34. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 348:2003;2186-2195
35. Youle M, Janossy G, Turnbull W, et al. Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens. AIDS. 14:2000;1717-1720
36. Tebas P, Henry K, Mondy K, et al. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies. J Infect Dis. 186:2002;851-854
37. Deeks SG, Barbour JD, Martin JN, Swanson MS, Grant RM. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis. 181:2000;946-953
38. Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS. 16:2002;201-207
39. Staszewski S, Miller V, Sabin C, et al. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. AIDS. 13:1999;951-956
40. Cozzi-Lepri A, Phillips AN, Miller V, et al. Changes in viral load in people with virological failure who remain on the same HAART regimen. Antivir Ther. 8:2003;127-136
41. Viard JP, Mocroft A, Chiesi A, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis. 183:2001;1290-1294
42. Hellmann NS, Wrin T, Bates M, et al. Modelling the effect of HIV replicative capacity on treatment outcomes. Antivir Ther. 7:2002;S70
43. Phillips AN, McLean A, Johnson MA, et al. HIV-1 dynamics after transient antiretroviral therapy: implications for pathogenesis and clinical management. J Med Virol. 53:1997;261-265
44. Rutschmann OT, Opravil M, Iten A, et al. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. AIDS. 12:1998;F71-77
45. Mocroft A, Ledergerber B, Viard JP, et al. Time to triple drug class failure after initiation of HAART. In: Program and abstracts of the 11th conference on retroviruses and opportunistic infections. San Francisco, CA; February, 2004: abstr 554.
46. Katlama C, Dominguez S, Duvivier C, et al. Long-term benefit of treatment interruption in salvage therapy (GIGHAART ANRS 097). In: Program and abstracts of the 10th conference on retroviruses and opportunistic infections. Boston, MA; February, 2003: abstr 68.
47. Montaner JS, Harrigan PR, Jahnke N, et al. Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. AIDS. 15:2001;61-69